Q-omics provides the consensus-scored USP6NL profile across patient tissues and cancer cell-line models. USP6NL expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, USP6NL is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, USP6NL RNA expression shows 20,112 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, COAD, and ACC as cancer lineages where USP6NL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for USP6NL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes USP6NL survival associations across molecular data types. USP6NL RNA expression shows survival associations in the most cancer types (29), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible USP6NL RNA expression–survival associations across cancer types. High USP6NL expression shows unfavorable associations in ACC and BLCA, but favorable associations in MESO, KIRC, HNSC and LUSC. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for USP6NL RNA expression.
This table summarizes USP6NL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for USP6NL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. USP6NL shows lower tumor expression in KICH and HNSC and higher tumor expression in COAD, BLCA, UCEC and CHOL. The COAD box plot shows higher USP6NL RNA expression in tumor versus normal tissue (log2 FC = +0.877, t-test p < 0.001).
This table shows molecular features associated with USP6NL in patient tissues and cancer cell lines. In patient samples, USP6NL shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, USP6NL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Lymphoma.
